4651-91-6 2-氨基-3-腈基-4,5,6,7-四氢苯并[B]噻吩

危险性质：非危险化学品

化学合成。

化学合成

合成路线 1（1. 合成：4651-91-6）

产率：99% 合成条件：With octasulfur; bovine serum albumin In N,N-dimethyl-formamide at 50℃; for 4 h; 实验步骤：通用方法：将1（1mmol），2（1mmol），元素硫（1mmol）和BSA（20mg）的混合物加入1mL DMF中。将反应在50℃和200rpm下温育。在所需时间后，将BSA过滤以终止反应。对于具有高产量的产品，固体粗产物在水中沉淀，然后过滤并干燥。对于产率低的产物，粗产物残留物经硅胶快速柱层析纯化，用石油醚/乙酸乙酯洗脱。产物结构经IR，1H NMR和13C NMR确证。使用TMS（四甲基硅烷）作为内参照，在Bruker Avance 400光谱仪上在CDCl 3中记录1H（400MHz）和13C NMR（100MHz）光谱。用Nicolet Nexus 470 FT-IR分光光度计获得IR光谱。 HPLC使用Agilent 1100系列和Agilent TC-C18柱（3a，3c，3e，3g，3i，3k：甲醇/水比= 60 / 40,1.0 mL / min和220 nm; 3b，3d，3f， 3h，3g，3l：甲醇/水比= 60 / 40,1.0mL / min和229nm）。对于所有反应，在使用前蒸馏用于柱色谱的溶剂.2.2.1。 2-氨基-4,5,6,7-四氢苯并[b]噻吩-3-甲腈（3a）黄色固体，熔点140-142℃（熔点[19]熔点144-146℃）。 IR（KBr）： 3447,3329,2198cm-1。 1H NMR（400MHz，CDCl3）:: 4.62（bs，2H），2.53-2.46（m，4H），1.85-1.73（m，4H）。 13 C NMR（100MHz，CDCl 3）:: 159.9,132.4,120.7,115.5,88.8,24.5,24.1,23.4,22.1。 参考文献：

• [1] Journal of Molecular Catalysis B: Enzymatic, 2013, vol. 95, p. 29 - 35 [2] Synlett, 2010, # 9, p. 1351 - 1354 [3] Synthetic Communications, 2010, vol. 40, # 14, p. 2067 - 2074 [4] Applied Organometallic Chemistry, 2018, vol. 32, # 5, [5] Patent: WO2005/44008, 2005, A2. Location in patent: Page/Page column 91 [6] Letters in Organic Chemistry, 2014, vol. 11, # 9, p. 700 - 705 [7] Tetrahedron Letters, 2007, vol. 48, # 18, p. 3171 - 3172 [8] Letters in Organic Chemistry, 2014, vol. 11, # 6, p. 403 - 408 [9] Heterocycles, 2014, vol. 88, # 1, p. 741 - 753 [10] Synthetic Communications, 2001, vol. 31, # 20, p. 3113 - 3117 [11] Synthetic Communications, 2012, vol. 42, # 16, p. 2367 - 2374 [12] Applied Organometallic Chemistry, 2017, vol. 31, # 11, [13] Bulletin of the Korean Chemical Society, 2011, vol. 32, # 6, p. 2091 - 2092 [14] Synthetic Communications, 2013, vol. 43, # 13, p. 1859 - 1864 [15] Journal of Sulfur Chemistry, 2014, vol. 35, # 3, p. 261 - 269 [16] Archiv der Pharmazie, 2016, vol. 349, # 11, p. 827 - 847 [17] Journal of Chemical Research, 2014, vol. 38, # 7, p. 450 - 452 [18] Synthetic Communications, 2015, vol. 45, # 1, p. 119 - 126 [19] Monatshefte fur Chemie, 2017, vol. 148, # 4, p. 711 - 716 [20] Research on Chemical Intermediates, 2018, vol. 44, # 3, p. 2195 - 2213 [21] Tetrahedron, 2006, vol. 62, # 29, p. 7121 - 7131 [22] Journal of Sulfur Chemistry, 2013, vol. 34, # 5, p. 458 - 463 [23] Journal of Molecular Catalysis A: Chemical, 2013, vol. 368-369, p. 16 - 23 [24] Applied Organometallic Chemistry, 2018, vol. 32, # 2, [25] Patent: US2010/81823, 2010, A1. Location in patent: Page/Page column 7 [26] Patent: CN104945412, 2018, B. Location in patent: Paragraph 0044; 0045 [27] European Journal of Medicinal Chemistry, 2013, vol. 66, p. 32 - 45 [28] European Journal of Medicinal Chemistry, 2017, vol. 138, p. 38 - 50 [29] Patent: US2009/275533, 2009, A1. Location in patent: Page/Page column 39 [30] Patent: US2010/120805, 2010, A1. Location in patent: Page/Page column 42-43 [31] Bioconjugate Chemistry, 2012, vol. 23, # 12, p. 2403 - 2416 [32] Medicinal Chemistry Research, 1996, vol. 6, # 3, p. 148 - 163 [33] Bioorganic and Medicinal Chemistry Letters, 2007, vol. 17, # 5, p. 1296 - 1301 [34] Patent: WO2006/58600, 2006, A1. Location in patent: Page/Page column 8-9 [35] Journal of Heterocyclic Chemistry, 2008, vol. 45, # 3, p. 853 - 857 [36] Patent: US2008/306053, 2008, A1. Location in patent: Page/Page column 57 [37] European Journal of Medicinal Chemistry, 2010, vol. 45, # 9, p. 4026 - 4034 [38] Archiv der Pharmazie, 2010, vol. 343, # 10, p. 590 - 601 [39] Russian Chemical Bulletin, 2011, vol. 60, # 2, p. 352 - 360 [40] Bioorganic and Medicinal Chemistry Letters, 2011, vol. 21, # 23, p. 7089 - 7093 [41] Egyptian Journal of Chemistry, 2010, vol. 53, # 4, p. 515 - 526 [42] Journal of Medicinal Chemistry, 2013, vol. 56, # 9, p. 3620 - 3635 [43] European Journal of Medicinal Chemistry, 2013, vol. 63, p. 924 - 934 [44] Journal of Sulfur Chemistry, 2013, vol. 34, # 3, p. 264 - 275 [45] Bioorganic and Medicinal Chemistry Letters, 2015, vol. 25, # 6, p. 1306 - 1309 [46] European Journal of Medicinal Chemistry, 2015, vol. 106, p. 1 - 14 [47] Chemical Biology and Drug Design, 2016, vol. 87, # 4, p. 499 - 507 [48] Tetrahedron Letters, 2016, vol. 57, # 22, p. 2455 - 2461 [49] Bioorganic and Medicinal Chemistry, 2016, vol. 24, # 18, p. 3972 - 3977 [50] Tetrahedron Letters, 2017, vol. 58, # 14, p. 1408 - 1412 [51] Chemical and Pharmaceutical Bulletin, 2017, vol. 65, # 5, p. 469 - 477 [52] Journal of Heterocyclic Chemistry, 2017, vol. 54, # 6, p. 3672 - 3681 [53] Chemical Biology and Drug Design, 2018, vol. 91, # 6, p. 1141 - 1155 [54] Bioorganic Chemistry, 2018, vol. 80, p. 693 - 705 [55] Bulletin of the Chemical Society of Ethiopia, 2018, vol. 32, # 2, p. 259 - 270

合成路线 2（3. 合成：4651-91-6）

产率：76.4% 合成条件：at 20℃; 实验步骤：一般步骤：将在15cm 3 THF中的0.8g叠氮化物1（3.9mmol）和4.1mmol二甲基，二乙基或亚磷酸二异丙酯（6a-6c）的混合物在室温下搅拌。 保持6-10小时（TLC）并在真空下除去挥发性物质。 将得到的残余物在硅胶上进行色谱分离，用正己烷/ CHCl 3（8：2，v / v）洗脱，得到2-氨基-4,5,6,7-四氢苯并 - [b]噻吩-3-甲腈（9）作为抛光剂 物质含量10.3％;熔点 147 C（参考文献[26] 145 C）。 用正己烷/ CHCl 3（1：1，v / v）洗脱，得到8a-8c。 参考文献：

• [1] Monatshefte fur Chemie, 2016, vol. 147, # 3, p. 619 - 626